Skip to content

Evaluation of High-Purity Type I Collagen Biologic Wrap to Improve Function After Extensor Tendon Repair of the Hand

A Randomized Controlled Trial Evaluating High-Purity Type I Collagen Wrap Around Extensor Tendon Repair Sites in Zones VI-VIII of the Hand to Prevent Adhesions and Improve Functional Outcomes

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07335653
Enrollment
60
Registered
2026-01-13
Start date
2025-12-05
Completion date
2026-02-26
Last updated
2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Injury of Extensor Tendon of Hand, Tendon Adhesions

Keywords

Extensor tendon repair, Tendon adhesion, High Purity Type I Collagen, Biologic wrap, Hand injuries

Brief summary

Tendon injuries of the hand, particularly extensor tendons, are prone to postoperative adhesions, extensor lag, and stiffness, leading to functional impairment. This multicentric randomized controlled trial evaluates whether wrapping repaired extensor tendons with a high-purity Type I collagen (HPTC) biologic membrane can reduce adhesion formation and improve functional outcomes compared with standard repair alone.

Detailed description

Extensor tendon injuries of the hand are common due to the superficial location of the tendons and the thin soft tissue envelope over the dorsum of the hand and wrist. These injuries, particularly in zones VI-VIII, are frequently associated with postoperative adhesions and extensor lag, leading to functional impairment and delayed return to work. Postsurgical adhesions may occur in up to 30-40% of tendon injuries and remain a major clinical challenge despite advances in suture techniques and rehabilitation protocols. Several strategies have been investigated to minimize tendon adhesions, including optimized suture techniques, early mobilization, anti-adhesive agents, and biologic barrier membranes. Recent clinical work has shown that wrapping repaired extensor tendons with an amniotic membrane in zone VI can improve range of motion (ROM), Quick DASH scores, and recovery time, suggesting a true reduction in peritendinous fibrosis. Experimental models have also demonstrated that collagen-glycosaminoglycan (GAG) wraps can reduce early postoperative tendon adhesions while preserving tendon healing strength. HPTC is a bioengineered, acellular dermal replacement product composed of \>97% pure Type I collagen, free of elastin, lipids, and immunogenic proteins. It is manufactured to preserve the native triple helical structure and bioactivity of collagen, providing a cell-conducive scaffold that promotes neovascularization, granulation tissue formation, and tissue remodelling. HPTC is flexible, translucent, moderately tacky, and can be cut, sutured or stapled, making it feasible to be fashioned as a wrap or sleeve around tendons. Multiple randomized controlled trials and clinical series by Narayan et al. have demonstrated the safety and efficacy of high-purity Type I collagen-based skin substitute HPTC in chronic and acute wounds. These studies collectively show that high-purity Type I collagen membranes are safe, well tolerated, promote faster wound healing, and have favourable scarring and pain profiles in a variety of clinical settings. Rationale for the Current Study - Given the strong biological plausibility of Type I collagen scaffolds as biocompatible, resorbable barriers that can modulate the healing milieu; the safety and clinical efficacy of HPTC in multiple wound types; and the demonstrated benefit of biologic wraps (e.g., amniotic membrane) around extensor tendon repairs in reducing adhesions, it is logical to evaluate whether a HPTC wrap around the repaired extensor tendon in zones VI-VIII can reduce adhesion-related stiffness and improve functional outcomes compared with standard repair alone. This trial will be, to our knowledge, the first prospective randomized clinical trial to assess HPTC as a tendon wrap in extensor tendon repairs of the hand.

Interventions

DEVICEHigh-Purity Type I Collagen (HPTC) Wrap

After completion of standard extensor tendon repair, a sterile high-purity Type I collagen sheet is hydrated, trimmed, and loosely wrapped circumferentially around the repaired tendon segment to act as a resorbable biologic barrier aimed at reducing peritendinous adhesions.

PROCEDUREStandard Extensor Tendon Repair

Primary extensor tendon repair using standard core and epitendinous sutures without use of any biologic wrap or anti-adhesion adjunct.

Sponsors

Adichunchanagiri Institute of Medical Sciences, B G Nagara
Lead SponsorOTHER
Mysore Medical College and Research Institute
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18-65 years. 2. Acute open laceration of extensor tendons in zone VI, VII, or VIII of the hand / wrist (according to Verdan's classification), involving digits 2-5 and/or wrist extensors. 3. Complete tendon laceration (≥50% tendon cross-sectional area), requiring primary repair. 4. Time from injury to surgical repair ≤72 hours. 5. Single upper limb involved. 6. Ability and willingness to comply with postoperative rehabilitation protocol and follow-up visits. 7. Provision of written informed consent.

Exclusion criteria

1. Crush, avulsion, or segmental tendon loss requiring graft or tendon transfer. 2. Associated open fractures requiring dorsal plating across the repair site, or extensive bone loss affecting joint stability. 3. Previous surgery or significant scarring over the injured extensor tendon region. 4. Associated major nerve injury requiring graft or complex reconstruction (digital nerve repair without grafting may be allowed if balanced between groups). 5. Uncontrolled systemic illness (e.g., HbA1c \> 8.5% for diabetes, severe peripheral vascular disease, chronic steroid use, severe malnutrition). 6. Active infection at the injury site. 7. Known allergy or hypersensitivity to bovine/ovine collagen or any component of HPTC. 8. Pregnancy or lactation. 9. Inability to provide informed consent or comply with follow-up.

Design outcomes

Primary

MeasureTime frameDescription
Total Active Motion (TAM) of Involved Finger(s)8 weeks postoperativelyTotal Active Motion (TAM) is calculated as the sum of active flexion at the metacarpophalangeal (MCP), proximal interphalangeal (PIP), and distal interphalangeal (DIP) joints minus the extension deficits. TAM is expressed in degrees. Higher values indicate better functional outcome.

Secondary

MeasureTime frameDescription
QuickDASH Score6 weeks and 8 weeks postoperativelyQuick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire assessing upper limb disability and symptoms. Lower scores indicate better function. Higher scores indicate greater impairment. Score Range 0 to 100.
Extensor Lag8 weeks postoperativelyExtensor lag was calculated as the total extension deficit (in degrees) across the metacarpophalangeal (MCP), proximal interphalangeal (PIP), and distal interphalangeal (DIP) joints of the involved finger(s). The deficits at each joint were summed to generate a single total extensor lag value. Lower values indicate better functional outcome.
Number of Participants With Clinically Significant Tendon AdhesionsUp to 8 weeks postoperativelyNumber of participants who developed clinically significant tendon adhesions within 8 weeks postoperatively. Clinically significant adhesion was defined as failure to achieve Total Active Motion (TAM) ≥60% of the contralateral digit despite adherence to rehabilitation protocol and/or requirement for surgical tenolysis. Higher values indicate greater frequency of adhesion-related complications.
Grip Strength8 weeks postoperativelyGrip strength measured using a calibrated Jamar dynamometer and expressed as a percentage of the contralateral uninvolved side. Higher values indicate better functional recovery.
Time to Return to Work or Activities of Daily LivingUp to 8 weeks postoperativelyNumber of days from surgery to return to pre-injury occupational or activities of daily living status.
Patient Satisfaction8 weeks postoperativelyPatient-reported satisfaction with hand function and appearance measured using Likert scale. Scale range: 1 to 10 (1 = very dissatisfied, 10 = very satisfied). Interpretation: Higher scores indicate greater patient satisfaction.

Countries

India

Contacts

STUDY_CHAIRPrema Dhanraj, MS, MCh

Rajarajeshwari Medical College and Hospital

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
60 Participants
Age, Continuous37.3 years
STANDARD_DEVIATION 10.9
Injury Complexity
Multiple tendon injuries
12 Participants
Injury Complexity
Single tendon injury
18 Participants
Injury Zone
Zone VI
29 Participants
Injury Zone
Zone VII
19 Participants
Injury Zone
Zone VIII
12 Participants
Race/Ethnicity, Customized
Asian (Indian)
30 Participants
Region of Enrollment
India
60 Participants
Sex: Female, Male
Female
10 Participants
Sex: Female, Male
Male
20 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 300 / 30
other
Total, other adverse events
0 / 301 / 30
serious
Total, serious adverse events
0 / 300 / 30

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026